Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 dec 2008 - 07:55
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Registration of Hepavax-Gene® in China
Bericht
Leiden, The Netherlands, 8 December 2008 – Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that the Chinese Authorities have released Hepavax-Gene® for registration and quality control in China.
“The launch of Hepavax-Gene® is a significant advancement in the expansion of Crucell’s business in the highly strategic Chinese vaccine market,” said Ronald Brus, Crucell's Chief Executive Officer. “Hepavax-Gene® will contribute significantly to the sustainability of our Chinese operations. The Chinese hepatitis B vaccine market is the world’s biggest market with approximately 100 million doses administered yearly.”
The prospects for Hepavax-Gene® in the Chinese private market are excellent. Hepavax-Gene® will be positioned in the high-end private market segment with a particular focus on young adults. Hepavax-Gene® possesses two decisive advantages; its production is based on Crucell’s hansenula polymorpha patented technology and it is 100% free of thiomersal. Thiomersal is a mercury based compound which, in several countries, is being phased out from vaccines given to children to avoid potentially adverse effects.
Gerelateerde downloads
Datum laatste update: 24 december 2025